Ann: New Indication for ATL1102 Limb Girdle Muscular Dystrophy R2, page-69

got a real chicken and egg feel about it doesn't it

If we don't have trial success is there any point in having a pipeline for other stuff? we could be wiped out??

if we are owning the DMD space and in fact are 'balls deep' in this potentially company making trial why don't we own the communication in regards to that and shout it from the rooftops as opposed to reporting all the new stuff

I get it's a balance, the effort could be

80% trial 20% other items

but the communication seems to be

20% trial 80% other indications

Gut feel is they are probably doing a stellar job 'on the tools' but are useless on comms - but that is no different to a lot of businesses in Aus